• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病在基层医疗中的影响:人群健康视角。

The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective.

机构信息

Department of Hospital Medicine, Catholic Medical Center, Manchester, NH.

Division of Gastroenterology and Hepatology, Mayo Clinic in Arizona, Scottsdale.

出版信息

Am J Med. 2021 Jan;134(1):23-29. doi: 10.1016/j.amjmed.2020.08.010. Epub 2020 Sep 12.

DOI:10.1016/j.amjmed.2020.08.010
PMID:32931760
Abstract

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide, with rising rates in parallel to those of obesity, type 2 diabetes, and metabolic syndrome. NAFLD encompasses a wide spectrum of pathology from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis, which are linked to poor outcomes. Studies confirm a significant amount of undiagnosed NAFLD and related fibrosis within the community, increasing the overall burden of the disease. NAFLD appears to be more prevalent in certain populations, such as those with type 2 diabetes and metabolic syndrome. Early detection and lifestyle modifications, including weight loss and regular exercise, have been shown to improve outcomes. Adverse cardiovascular events are a key contributor to NAFLD-associated morbidity and mortality, and efforts to minimize their occurrence are essential. A targeted and algorithmic approach using noninvasive diagnostic techniques is promptly required to identify and risk-stratify patients with NAFLD. Patients at low risk of progression to NASH and advanced fibrosis can be managed in the primary care setting, while those at high risk of disease progression should be referred to hepatology specialists for surveillance and treatment. This review summarizes the key data of NAFLD's impact within primary care populations and proposes a potential algorithmic approach to identifying and managing such patients.

摘要

非酒精性脂肪性肝病(NAFLD)是全球范围内导致肝脏疾病的主要原因,其发病率与肥胖症、2 型糖尿病和代谢综合征的发病率呈平行上升趋势。NAFLD 涵盖了从单纯性脂肪变性到非酒精性脂肪性肝炎(NASH)和肝硬化的广泛病理学谱,这些疾病与不良结局相关。研究证实,社区中存在大量未确诊的 NAFLD 和相关纤维化,这增加了疾病的总体负担。NAFLD 在某些人群中似乎更为普遍,例如 2 型糖尿病和代谢综合征患者。早期发现和生活方式改变,包括减肥和定期锻炼,已被证明可以改善结局。不良心血管事件是导致 NAFLD 相关发病率和死亡率的关键因素,因此努力降低其发生至关重要。需要使用非侵入性诊断技术,采用有针对性和算法性的方法,及时识别和风险分层 NAFLD 患者。进展为 NASH 和晚期纤维化风险较低的患者可以在初级保健环境中进行管理,而疾病进展风险较高的患者应转介给肝病专家进行监测和治疗。本综述总结了 NAFLD 在初级保健人群中的重要数据,并提出了一种潜在的算法方法来识别和管理此类患者。

相似文献

1
The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective.非酒精性脂肪性肝病在基层医疗中的影响:人群健康视角。
Am J Med. 2021 Jan;134(1):23-29. doi: 10.1016/j.amjmed.2020.08.010. Epub 2020 Sep 12.
2
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的临床流行病学和疾病负担。
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263.
3
Nonalcoholic Steatohepatitis: A Review.非酒精性脂肪性肝炎:综述。
JAMA. 2020 Mar 24;323(12):1175-1183. doi: 10.1001/jama.2020.2298.
4
Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.非酒精性脂肪性肝病应在 2 型糖尿病的标准管理算法中考虑作为治疗分配的因素。
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2233-2239. doi: 10.1016/j.dsx.2020.11.015. Epub 2020 Nov 19.
5
Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.土耳其非酒精性脂肪性肝病负担日益加重:单中心经验
Turk J Gastroenterol. 2019 Oct;30(10):892-898. doi: 10.5152/tjg.2019.19072.
6
Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.2017 - 2030年沙特阿拉伯和阿拉伯联合酋长国的非酒精性脂肪性肝病负担
Saudi J Gastroenterol. 2018 Jul-Aug;24(4):211-219. doi: 10.4103/sjg.SJG_122_18.
7
Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques.使用非侵入性检测和成像技术评估重度肥胖中的非酒精性脂肪性肝病(NAFLD)。
Obes Rev. 2022 Aug;23(8):e13481. doi: 10.1111/obr.13481. Epub 2022 Jun 12.
8
Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai'i.非酒精性脂肪性肝病:夏威夷初级保健提供者的重要考虑因素。
Hawaii J Health Soc Welf. 2020 Jun 1;79(6):180-186.
9
Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting.非酒精性脂肪性肝病筛查在基层医疗环境中的 2 型糖尿病患者。
Hepatol Commun. 2020 Oct 31;5(2):158-167. doi: 10.1002/hep4.1618. eCollection 2021 Feb.
10
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.建立中国、法国、德国、意大利、日本、西班牙、英国和美国 2016-2030 年非酒精性脂肪性肝病疾病负担模型。
J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.

引用本文的文献

1
Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: a qualitative study.从胃肠病学和肝病学专家角度看非酒精性脂肪性肝病管理中的挑战与需求:一项定性研究
BMC Gastroenterol. 2025 May 22;25(1):396. doi: 10.1186/s12876-025-03921-z.
2
High-Fat Diet Delays Liver Fibrosis Recovery and Promotes Hepatocarcinogenesis in Rat Liver Cirrhosis Model.高脂饮食延缓大鼠肝硬化模型肝纤维化的恢复并促进肝癌发生。
Nutrients. 2024 Aug 1;16(15):2506. doi: 10.3390/nu16152506.
3
Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?
营养保健品能否支持 MASLD/MASH 的治疗,从而影响肝纤维化的进程?
Int J Mol Sci. 2024 May 11;25(10):5238. doi: 10.3390/ijms25105238.
4
IL-27 increases energy storage in white adipocytes by enhancing glucose uptake and fatty acid esterification.IL-27 通过增强葡萄糖摄取和脂肪酸酯化来增加白色脂肪细胞的能量储存。
Adipocyte. 2023 Dec;12(1):2276346. doi: 10.1080/21623945.2023.2276346. Epub 2023 Nov 10.
5
The Association of Nonalcoholic Fatty Liver Disease With Neutrophil-to-Lymphocyte Ratio and Neutrophil-Percentage-to-Albumin Ratio.非酒精性脂肪性肝病与中性粒细胞与淋巴细胞比值及中性粒细胞百分比与白蛋白比值的关联
Cureus. 2023 Jun 30;15(6):e41197. doi: 10.7759/cureus.41197. eCollection 2023 Jun.
6
Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.金雀花堿,一种有潜力的口服小分子胰高血糖素样肽-1 受体激动剂,可降低血糖并改善非酒精性脂肪性肝炎。
Drug Des Devel Ther. 2023 May 11;17:1417-1432. doi: 10.2147/DDDT.S404055. eCollection 2023.
7
To scan or not to scan: Use of transient elastography in an integrated health system.扫描还是不扫描:瞬时弹性成像技术在综合医疗系统中的应用
World J Hepatol. 2023 Mar 27;15(3):419-430. doi: 10.4254/wjh.v15.i3.419.
8
Non-alcoholic fatty liver disease in diabetes mellitus patients on chronic hemodialysis - A case series addressing cardiovascular and mortality risks.糖尿病慢性血液透析患者的非酒精性脂肪性肝病——一组探讨心血管和死亡风险的病例
Front Clin Diabetes Healthc. 2023 Feb 9;4:1113666. doi: 10.3389/fcdhc.2023.1113666. eCollection 2023.
9
Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes.基于超声的非酒精性脂肪性肝病肝脏弹性成像:聚焦2型糖尿病患者
Biomedicines. 2022 Sep 23;10(10):2375. doi: 10.3390/biomedicines10102375.